Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28638036 | 1.00 | FAP (0.35) | FAP | |
| SCHEMBL28638033 | 1.00 | FAP (0.35) | FAP | |
| SCHEMBL22154614 | 0.93 | SMN1; SMN2 (0.36) | FAP | |
| SCHEMBL28633861 | 0.93 | SMN1; SMN2 (0.36) | FAP | |
| SCHEMBL22154266 | 0.92 | FAP (0.36) | FAP | |
| SCHEMBL28628684 | 0.92 | FAP (0.36) | FAP | |
| SCHEMBL28628682 | 0.92 | FAP (0.36) | FAP | |
| SCHEMBL22154590 | 0.92 | FAP (0.37) | FAP | |
| SCHEMBL28634363 | 0.92 | FAP (0.37) | FAP | |
| SCHEMBL28634362 | 0.92 | FAP (0.37) | FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4171653-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Regeneron Pharmaceuticals, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230069722-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132658-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069722-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | FAP 2777/4885 |
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | FAP 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.